Publication Details - Overview

This activity is part of PER's Integrated Oncology Learning Series: A Focus on Chronic Lymphocytic Leukemia

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Advances in Frontline Therapy for Chronic Lymphocytic Leukemia

Oncology Briefings Vol. 7, No. 2

0.5 AMA PRA Category 1 Credit(s)™
Release Date: August 25, 2009
Expiration Date: August 25, 2010

Publication Overview

Authors

Medical writer: Sabeeha Muneer, PhD; Reviewed by: Emili Montserrat, MD

Overview and Purpose

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world, with approximately 15,000 new cases diagnosed in the United States annually. For frontline management of patients with CLL, current guidelines recommend the use of purine analogues and alkylating agents either alone or in combination. Although these chemotherapy approaches yield a relatively high proportion of responses, they have been unsuccessful in producing sustained and durable responses. This past decade has witnessed the introduction of new treatment strategies, including the use of monoclonal antibodies (MoAbs) in combination with chemotherapy regimens, that have changed the therapeutic landscape for CLL and have yielded improved response rates and prolongation of disease-free survival. In an effort to further improve clinical outcomes and deepen achieved remissions, new MoAbs against novel molecular targets, cytotoxic agents, and other biologic agents are being clinically tested as frontline therapy for patients with CLL.

The purpose of this activity is to update physicians on emerging treatment strategies for the management of patients with previously untreated CLL.

Target Audience

This educational activity is intended for medical oncologists and hematologists involved in the care of patients with CLL. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.

Learning Objectives

Upon completion of this educational activity, you should be able to:

  • Discuss the use of purine analogue–based chemoimmunotherapy regimens in patients with previously untreated CLL
  • Describe the characteristics of second- and third-generation anti-CD20 MoAbs
  • Assess the use of bifunctional alkylators and other treatment strategies in patients with previously untreated CLL

Instructions for Participation

  1. Read the following information before entering the educational activity.
  2. Complete the Pretest.
  3. Study the educational activity.
  4. Complete the Posttest.
  5. Answer the evaluation questions.
  6. After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.

You will be permitted 2 attempts to successfully complete the Posttest.

The tests and evaluation must be completed by August 25, 2010, in order for you to receive your certificate.

CME credit will be granted for only 1 form of participation, either online or via the printed publication.

Complete the test(s) and evaluation by August 25, 2010 to receive your certificate online.

Read all of the conditions in the Activity Terms box below. You must accept the CME Activity Terms in order to continue:

Disclosure Policy

It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

Sabeeha Muneer, PhD
No relevant relationships to disclose

Emili Montserrat, MD
Research Funding – Gilead, Roche Pharmaceuticals
Paid Consultant – Celgene Corporation, GlaxoSmithKline, Roche Pharmaceuticals

Other PER Staff
No relevant relationships to disclose

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is located on the title page. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Commercial Support
An educational grant for this activity was provided by GlaxoSmithKline.

Software Requirements
The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Additional software requirements include:

Macintosh Users
Compatible Web browsers include:

Additional software requirements include:

Banner Illustration
Illustrator: Pam Curry

Disclaimer
The views and opinions expressed in this activity are those of the authors and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the authors and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

This activity is not sanctioned by, nor a part of, the 50th ASH Annual Meeting and Exposition or the 14th Congress of the European Hematology Association.

Privacy Policy
Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2009 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, Advances in Frontline Therapy for Chronic Lymphocytic Leukemia
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@cancerlearning.com

8623

Educational Grants

An educational grant for this activity was provided by:


  1. GlaxoSmithKline